Two-target antibodies sharpen cancer attack, enabling even more complex multispecific therapies
Bispecific antibodies that bind two targets are rapidly moving into the clinic and becoming more elaborate, with the number of approved drugs rising from 3 to over 20 in five years and 2025 sales around $18 billion. Most work as T cell engagers that recruit immune cells to cancer, but researchers are developing multispecifics that target three or more components to boost efficacy, reduce toxicity to healthy cells, and counter resistance. Advances in protein production and AI are enabling these complex designs, signaling a shift toward smarter, more selective cancer therapies.